Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins

Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops. In this study, we assessed the efficacy of the highly potent and selective MCL-1 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yijing, Lee, Heng-Huan, Jiang, Vivian Changying, Che, Yuxuan, McIntosh, Joseph, Jordan, Alexa, Vargas, Jovanny, Zhang, Tianci, Yan, Fangfang, Simmons, Margaret Elizabeth, Wang, Wei, Nie, Lei, Yao, Yixin, Jain, Preetesh, Wang, Michael, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622549/
https://www.ncbi.nlm.nih.gov/pubmed/37919300
http://dx.doi.org/10.1038/s41419-023-06233-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622549/
https://www.ncbi.nlm.nih.gov/pubmed/37919300
http://dx.doi.org/10.1038/s41419-023-06233-w

Ejemplares similares